Containing At Least One Abnormal Peptide Link, E.g., Gamma Peptide Bonded, Etc. Patents (Class 530/332)
-
Patent number: 11952406Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: GrantFiled: June 2, 2023Date of Patent: April 9, 2024Assignee: OTHAIR PROTHENA LIMITEDInventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Patent number: 11364275Abstract: Disclosed herein are linear lipopeptides having antimicrobial and antibiofilm activity. In one aspect of the invention the linear lipopeptide comprising a lipophilic terminus, an amine terminus, and a peptide interposed between the lipophilic terminus and the amine terminus or a salt thereof. The peptide may comprise any of SEQ ID Nos: 1-17 or a derivative thereof. Products comprising the lipopeptides and methods of using the same are also disclosed.Type: GrantFiled: August 6, 2018Date of Patent: June 21, 2022Assignee: BioVentures, LLCInventors: En Huang, Sun Hee Moon, Mark Smeltzer, Daniel Meeker
-
Patent number: 10272130Abstract: The disclosure relates to compositions, methods and systems for treating cellular oxidative stress in a user. A composition of the disclosure includes an effective amount of reduced glutathione for reducing oxidative stress in the user and a deoxygenated water solvent. The composition is encapsulated in a phospholipid liposome structure and packaged and stored in an airless dispenser configured to maintain an anaerobic environment.Type: GrantFiled: April 17, 2018Date of Patent: April 30, 2019Inventors: Stephen N. Pitcher, Danny Clinton Purser
-
Patent number: 9834579Abstract: Disclosed are two novel crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallization of SAG from mixtures of water-acetone, water-ethanol or water acetone under controlled conditions. Forms A and B can be advantageously used as ingredients of pharmaceutical or nutraceutical formulations.Type: GrantFiled: November 6, 2014Date of Patent: December 5, 2017Assignee: Gnosis S.p.A.Inventors: Davide Bianchi, Marco Valetti, Paola Bazza
-
Patent number: 9669080Abstract: The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.Type: GrantFiled: March 7, 2013Date of Patent: June 6, 2017Assignees: INVECTYS, Universite De Franche-Comte, Centre Hospitalier Regional Universitaire De BesanconInventors: Pierre Langlade Demoyen, Olivier Adotevi, Magalie Dosset
-
Patent number: 9399661Abstract: The present invention relates to peptide copper catalysts capable of oxidizing hydrocarbons at room temperature.Type: GrantFiled: July 31, 2015Date of Patent: July 26, 2016Assignee: University of The West IndiesInventors: Gurdial Singh, Latisha Candice Nicholas-Lewis
-
Patent number: 8980845Abstract: The present invention relates to a process for the enzymatic production of a dipeptide composition from a cyanophycin (CGP) or CGP-like polymer preparation by degrading the polymer preparation with an CGPase, a CGPase particularly adapted for said process, and the use of cyanophycin (CGP) or CGP-like polymers or fragments thereof, notably a dipeptide composition obtained by the process as defined above, as pharmaceutical composition, medicament, or as food or feed substitute.Type: GrantFiled: June 15, 2009Date of Patent: March 17, 2015Assignee: Westfälische Wilhelms-Universität MünsterInventors: Ahmed Sallam, Alexander Steinbüchel
-
Patent number: 8981054Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.Type: GrantFiled: March 11, 2011Date of Patent: March 17, 2015Assignee: Ipsen Pharma S.A.S.Inventors: Rakesh Datta, Zheng Xin Dong
-
Patent number: 8975368Abstract: Peptide nanotube polymers and methods of making such are disclosed. The peptide nanotube polymers are comprised of alternating monomers of the first peptide ring and monomers of the second peptide ring covalently bonded to one another via a linker, and can be functionalized. The described peptide nanotube polymers can enjoy the combined properties of healing and toughness, self-reporting, and tunability and actuation.Type: GrantFiled: August 12, 2010Date of Patent: March 10, 2015Assignee: The United States of America, as represented by the Secretary of the NavyInventors: John L. Kulp, III, Manoj K. Kolel-Veetil, Thomas D. Clark
-
Patent number: 8952128Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.Type: GrantFiled: October 31, 2013Date of Patent: February 10, 2015Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
-
Patent number: 8900880Abstract: The present invention relates to an antigenically effective peptide comprising, from the amino to the carboxylic terminal, the amino acid sequence: G P P W W P P I C D P P Q P S K T Q G Q S X1 G Q S X2 G X3 G X4 G X5 G X6 G X7 G K G K S X8 D K Q X9 K P G G P W X10 P E P (SEQ ID No. 1), wherein the amino acids X1-X10 are selected independently from an arginine residue or a citrulline residue and at least one of X1-X10 is a citrulline residue, or a functional fragment thereof and uses thereof.Type: GrantFiled: November 22, 2010Date of Patent: December 2, 2014Assignee: Toscana Biomarkers S.R.L.Inventors: Paola Migliorini, Federico Pratesi
-
Patent number: 8883963Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity.Type: GrantFiled: December 10, 2008Date of Patent: November 11, 2014Assignee: Cadila Healthcare LimitedInventors: Rajesh H. Bahekar, Mukul R. Jain, Pankaj Ramanbhai Patel
-
Patent number: 8846615Abstract: The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides between two and six amino acids in length are provided, as well as analogs of these MNTF peptides that are modified by covalent attachment to another moiety. Other embodiments are described herein.Type: GrantFiled: February 23, 2009Date of Patent: September 30, 2014Assignee: Genervon Biopharmaceuticals, LLCInventors: Pui-Yuk Dorothy Ko, Mark S. Kindy
-
Patent number: 8796027Abstract: A nucleic acid is effectively introduced into a cell while suppressing the cytotoxicity by administering a nucleic acid complex comprising a high molecular weight derivative of ?-poly-L-lysine and a nucleic acid to a cell.Type: GrantFiled: April 25, 2006Date of Patent: August 5, 2014Assignees: JNC CorporationInventors: Takeshi Nagasaki, Seiji Shinkai, Atsushi Uno, Mamoru Nishida
-
Patent number: 8772450Abstract: Disclosed are ?-amino acid monomers containing cylcoalkyl, cycloalkenyl, and heterocylic substituents which encompass the ? and ? carbons of the peptide backbone and ?-polypeptides made from such monomers. Method of generating combinatorial libraries of polypeptides containing the ?-peptide residues and libraries formed thereby are disclosed.Type: GrantFiled: May 3, 2012Date of Patent: July 8, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Samuel H. Gellman, Daniel H. Appella, Hee-Seung Lee, Paul LePlae, Emilie Porter, Xifang Wang, Matthew Woll
-
Patent number: 8765909Abstract: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids, the metastin derivatives of the present invention achieve more improved blood stability, solubility, etc., reduced gelation tendency, improved pharmacokinetics, as well as exhibit an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity. The metastin derivatives of the present invention also have a gonadotropic hormone secretion suppressing activity, sex hormone secretion suppressing activity, etc.Type: GrantFiled: October 24, 2007Date of Patent: July 1, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa
-
Patent number: 8754049Abstract: A cyclic organic compound which comprises 16 amino acids or 17 amino acids and has no carboxyl group C-terminally and/or no amino group N-terminally. Optionally, one of the amino acids is a nonnatural amino acid. The ring closure is formed between a side chain of one amino acid and the C-terminus of another amino acid, or the ring closure is effected with the aid of a nonnatural amino acid. A process for producing and using the compound for regulating vectorial ion channels, for treating diseases associated with the lung function and for treating oedemas is provided.Type: GrantFiled: January 12, 2011Date of Patent: June 17, 2014Assignee: APEPTICO Forschung und Entwicklung GmbHInventors: Bernhard Fischer, Rudolf Lucas, Susan Tzotzos
-
Patent number: 8754191Abstract: This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid.Type: GrantFiled: February 8, 2012Date of Patent: June 17, 2014Assignees: Boston Probes, Inc., Dako Denmark A/SInventors: Kirsten Vang Nielsen, Jens J. Hyldig-Nielsen, Brett F. Williams
-
Patent number: 8709998Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.Type: GrantFiled: April 21, 2004Date of Patent: April 29, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Yeelena Shen, Jeanne Mary Comstock, Sun H. Kim
-
Patent number: 8623385Abstract: The present disclosure relates to crystalline form of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same.Type: GrantFiled: August 11, 2010Date of Patent: January 7, 2014Assignee: Novartis AGInventors: Jeewan Thakur, Dong Yang, Lili Feng
-
Patent number: 8609609Abstract: Host RNA/viral protein interaction as a target of intervention in the replication of viruses, e.g., the human immunodeficiency virus (HIV) are described. The target being upstream of the final replication product, and being crucial to the viral replication, is less likely to be genetically altered to drug resistance. Peptides that intervene in this RNA/viral protein interaction are also described, as well as compositions containing the same and methods of use thereof.Type: GrantFiled: January 16, 2009Date of Patent: December 17, 2013Assignee: North Carolina State UniversityInventor: Paul F. Agris
-
Publication number: 20130274440Abstract: The present invention concerns a new dimedon derivative and a method for the purification of PNA and peptide oligomers.Type: ApplicationFiled: April 8, 2013Publication date: October 17, 2013Inventors: Anette JACOB, Jörg HOHEISEL, Marc DAUBER, Manfred WIESSLER, Peter LORENZ, Heinz FLEISCHHACKER, Hans-Christian KLIEM
-
Patent number: 8551956Abstract: The invention relates generally to peptides comprising one or more non-natural amino acids residues and their use in cosmetic and personal care compositions.Type: GrantFiled: February 28, 2007Date of Patent: October 8, 2013Assignee: Avon Products, Inc.Inventor: Dmitri S. Ptchelintsev
-
Patent number: 8497349Abstract: A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).Type: GrantFiled: April 22, 2007Date of Patent: July 30, 2013Assignee: Centre National de la Recherche Scientifique (CNRS)Inventors: José Courty, Ara Hovanessian, Jean Paul Briand, Gilles Guichard, Yamina Hamma
-
Publication number: 20130190248Abstract: The present invention relates to peptide analogs, antibody-drug conjugates comprising such compounds, pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates.Type: ApplicationFiled: July 24, 2012Publication date: July 25, 2013Applicant: AGENSYS, INC.Inventors: Brian Alan MENDELSOHN, Stuart Daniel BARNSCHER
-
Patent number: 8487079Abstract: Provided herein are methods for using mitochondria-targeted electron scavengers as anti-inflammatory agents. The mitochondria-targeted electron scavenger comprises a free radical-scavenging group covalently linked to a mitochondria-targeting group derived from a hemigramicidin moiety. The mitochondria-targeted electron scavenger can be used to treat medical conditions associated with acute or chronic inflammation.Type: GrantFiled: August 8, 2008Date of Patent: July 16, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Mitchell P. Fink, Peter Wipf
-
Publication number: 20130150264Abstract: This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid.Type: ApplicationFiled: February 8, 2012Publication date: June 13, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Kirsten NIELSON, Jens J. Hyldig-Nielsen, Brett F. Williams
-
Patent number: 8435956Abstract: The present invention provides compositions and methods for protecting cells and tissues from damage associated with therapeutic treatments of cancers and other diseases and conditions where reactive oxygen species are produced. The present invention also provides compositions useful as research reagents.Type: GrantFiled: May 11, 2012Date of Patent: May 7, 2013Assignee: Percitus Biosciences, LLCInventor: James P. Thomas
-
Patent number: 8394922Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: GrantFiled: July 29, 2010Date of Patent: March 12, 2013Assignee: Medarex, Inc.Inventors: Heng Cheng, Qiang Cong, Sanjeev Gangwar
-
Patent number: 8383595Abstract: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition for promoting lacrimal secretion comprising a peptide derivative represented by the formula (I): and a contact lens which retains and/or contains the composition are provided.Type: GrantFiled: June 15, 2009Date of Patent: February 26, 2013Assignees: Kinki University, Fuso Pharmaceutical Industries, Ltd.Inventors: Atsufumi Kawabata, Hiroyuki Nishikawa, Yoshiko Kawai
-
Patent number: 8378066Abstract: The present invention relates to the preparation of insulinotropic peptides that are synthesized using a solid and solution phase (“hybrid”) approach. Generally, the approach includes synthesizing three different peptide intermediate fragments using solid phase chemistry. Solution phase chemistry is then used to add additional amino acid material to one of the fragments. The fragments are then coupled together in the solution phase. The use of a pseudoproline in one of the fragments eases solid phase synthesis of that fragment and also eases subsequent solution phase coupling of this fragment to other fragments. The present invention is very useful for forming insulinotropic peptides such as Exenatide(1-39) and its natural and non-natural counterparts.Type: GrantFiled: October 24, 2008Date of Patent: February 19, 2013Assignee: Corden Pharma Colorado, Inc.Inventors: Barry Thomas King, Paul Adam Bury, Richard A. Gabel, John Edward Crider, Robert Thad Carr, II, Bradley S. DeHoff
-
Publication number: 20120329987Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: August 28, 2012Publication date: December 27, 2012Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Patent number: 8334364Abstract: [Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a high therapeutic effect at a low dose. [Means For Solving Problems] Disclosed is a high molecular weight derivative of a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the carboxyl group in the side chain is bound to a hydroxyl group in the nucleoside derivative via an ester bond. Also disclosed is a method for producing the high molecular weight derivative.Type: GrantFiled: November 1, 2007Date of Patent: December 18, 2012Assignee: Nipon Kayaku Kabushiki KaishaInventors: Keiichiro Yamamoto, Kazutoshi Takashio
-
Publication number: 20120289681Abstract: A phosphorescent compound of general Formula I, or phosphorescent analogs thereof, wherein: at least one of R1 to R4 has a formula X—Y, wherein Y is a peptide sequence providing cell penetration, and X is absent or is a chemical linker; the or each of the remaining R1 to R4 groups are, independently, lipophilic, uncharged chemical groups; and Me is selected from Pt2+ or Pd2+, which probe is capable of measurement of molecular oxygen within live respiring cells by quenched-phosphorescence detection.Type: ApplicationFiled: June 8, 2009Publication date: November 15, 2012Applicant: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND CORKInventors: Dmitri Papkovsky, Ruslan Dmitriev
-
Patent number: 8258099Abstract: The invention is directed to peptide modulators of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer or neurodegenerative disease.Type: GrantFiled: July 15, 2005Date of Patent: September 4, 2012Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V., Beth Israel Deaconess Medical Center, Inc., The Salk Institute for Biological StudiesInventors: Kun Ping Lu, Robert K. Suto, Janusz M. Sowadski, Gunter S. Fischer, Joseph P. Noel, Mark Verdecia
-
Publication number: 20120178156Abstract: The present invention relates to a nucleic acid molecule comprising an annexin A5 (ANXA5) gene regulation element which comprises at least one point mutation, corresponding to nucleotide 186 (G to A), 203 (A to C), 229 (T to C), and 276 (G to A) of SEQ ID NO: 2, a vector comprising the nucleic acid molecule, and a host transformed with the vector. The invention also relates to specific uses, in particular diagnostic uses of the nucleic acid molecules described herein. The invention also relates to haplotyping an ANXA5 gene regulation element from a nucleic acid from an individual which involves determining nucleotides present at positions 186, 203, 229 and 276 of the individual's copy of the ANXA5 gene regulation element, by comparison to SEQ ID NO: 2.Type: ApplicationFiled: January 13, 2012Publication date: July 12, 2012Inventors: Nadja Bogdanova, Arseni Markoff, Jürgen Horst, Volker Gerke
-
Patent number: 8188222Abstract: [Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a higher therapeutic effect at a lower dose. [Means for Solving Problems] Disclosed is a high molecular weight derivative a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the nucleoside derivative is bound to the carboxyl group in the side chain of the high molecular weight compound via a highly hydrophobic linker.Type: GrantFiled: November 6, 2007Date of Patent: May 29, 2012Assignee: Nippon Kayaku Kabushiki KaishaInventors: Keiichiro Yamamoto, Kazutoshi Takashio
-
Publication number: 20120115796Abstract: The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: —NH—(CH2)?—[O—(CH2)?]?—O?—(CH2)?—Y— wherein ?, ?, ?, ?, and ? are each integers whose values are independently selected.Type: ApplicationFiled: April 4, 2011Publication date: May 10, 2012Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, David Tumelty, Qun Yin
-
Patent number: 8124726Abstract: According to the present invention, there is provided a range of new conotoxin derivatives and methods for synthesizing these analogues and other intramolecular dicarba bridge-containing peptides, including dicarba-disulfide bridge-containing peptides.Type: GrantFiled: May 20, 2009Date of Patent: February 28, 2012Assignees: Monash University, Polychip Pharmaceuticals Pty Ltd.Inventors: Andrea Robinson, Jomana Elaridi
-
Publication number: 20120046445Abstract: A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.Type: ApplicationFiled: November 2, 2011Publication date: February 23, 2012Inventors: Ae-June WANG, Chi-Heng Jian, Shyn-Dar Li, Yi-Fong Lin, Shin-Jr Liu
-
Publication number: 20120021530Abstract: Disclosed are isolated, unnatural polypeptides containing cyclically-constrained ?-amino acid residues and cyclically-constrained ?-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.Type: ApplicationFiled: November 16, 2010Publication date: January 26, 2012Inventors: Samuel H. Gellman, Ahlke Hayen, Margaret A. Schmitt, Felix N. Ngassa
-
Patent number: 8008440Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a ?bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a ?bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a ?bivalent radical, a —(CH2)t— bivalent radical, or a covalent bond; and where part (T) is a —Y-L-Z- radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for the preparation of these compounds in a combinatorial manner, is also disclosed.Type: GrantFiled: December 22, 2006Date of Patent: August 30, 2011Assignee: Tranzyme Pharma Inc.Inventors: Pierre Deslongchamps, Yves Dory, Gilles Berthiaume, Luc Ouellet, Ruoxi Lan
-
Patent number: 7989587Abstract: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.Type: GrantFiled: September 19, 2008Date of Patent: August 2, 2011Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Maha Ayyoub, Danila Valmori
-
Patent number: 7964181Abstract: Ring-constrained amino acid surrogates of formula I: where R1, R2, R3, R4, R5, R6a, R6b, R7, and y are as defined in the specification, methods for synthesizing ring-constrained amino acid surrogates of formula I, methods of use of ring-constrained amino acid surrogates of formula I, including use in linear or cyclic compounds which include a plurality of amino acid residues and one or more ring-constrained amino acid surrogates of formula I and linear or cyclic compounds which include a plurality of amino acid residues and one or more ring-constrained amino acid surrogates of formula I.Type: GrantFiled: March 30, 2007Date of Patent: June 21, 2011Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang, Hui-Zhi Cai
-
Patent number: 7915223Abstract: A novel class of antimicrobial polymeric agents, which include a plurality of amino acid residues, such as positively charged amino acid residues, and at least one hydrophobic residue linking therebetween, such as an omega-amino-fatty acid residue, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto, and a process of preparing same, are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same.Type: GrantFiled: August 8, 2006Date of Patent: March 29, 2011Assignee: Technion Research & Development Foundation Ltd.Inventors: Amram Mor, Inna Radzishevsky
-
Publication number: 20110046348Abstract: The invention relates to methods of preparing peptide hydrazides useful in as intermediates in preparing derivatized peptides and amenable to conversion to reactive azide comprising species. The invention relates to chemical methods of preparing such species from protected peptide-resins containing the aspartyl or glutamyl residues with orthogonal side-chain carboxylic acid protecting groups ester of Asp and Glu.Type: ApplicationFiled: May 11, 2009Publication date: February 24, 2011Inventor: Marian Kruszynski
-
Patent number: 7834141Abstract: Specially designed non-mammalian GnRH analogs resistant to degradation by the tumor tissue enzymes, post-proline peptidases as well as endopeptidases, are disclosed. The GnRH analogs are further defined as analogs of chicken II GnRH, salmon GnRH, or herring GnRH, but can include any non-mammalian GnRH analog with similar amino acid structure. These non-mammalian analogs incorporate D-arginine, D-leucine, D-tBu-Serine or D-Trp or other similar amino acids at position 6 and ethylamide or aza-Gly-amide or similar amides at position 10. These analogs demonstrate preferential binding to tumor cell GnRH receptors that is greater relative to the binding of the mammalian analogs to the tumor cell GnRH receptor. These non-mammalian GnRH analogs may be used in pharmaceutical preparations, and it specifically in various treatments as an anti-tumor, anti-proliferation, anti-metastatic and/or an apoptotic agent.Type: GrantFiled: March 31, 2000Date of Patent: November 16, 2010Inventors: Theresa Siler-Khodr, Gabriel S. Khodr
-
Publication number: 20100242141Abstract: The composition, in accordance with the present invention, for producing a plant body having an improved sugar content includes glutathione, a polynucleotide encoding ?-glutamylcysteine synthetase, or a polynucleotide encoding glutathione-binding plastid type fructose-1,6-bisphosphate aldolase. The composition preferably includes oxidized glutathione. This allows provision of a composition for easily producing a plant body having an improved sugar content.Type: ApplicationFiled: November 7, 2008Publication date: September 23, 2010Applicants: Japan Science and Technology Agency, Okayama PrefectureInventor: Kenichi Ogawa
-
Patent number: 7795401Abstract: The present invention relates generally to a modified hemoglobin with an allosteric effector conjugated which is capable of dynamically regulating the efficiency of oxygen release. The hemoglobin composition provided in the present invention is utilizing maleimide-Polyethylene glycol-N-hydroxysuccinimidyl as a linker to crossbridge the peptide comprising SEQ ID NO: 1 to the surface of a hemoglobin, and hence, it is able to decrease the oxygen affinity through the characteristic of the peptide which could enter into the central cavity formed between ?- chains of hemoglobin under an appropriate oxygen concentration.Type: GrantFiled: September 6, 2006Date of Patent: September 14, 2010Assignee: National Chung Cheng UniversityInventors: Kuang-Tse Huang, Yen-Lin Lin
-
Publication number: 20100222549Abstract: A dechalcogenative method for the preparation of an allylic sulfide comprises contacting an activated chalcogenide of Formula (I) with a thiol of Formula (II) for a period of time sufficient to form an intermediate of Formula (III), and supplying sufficient activation energy to the intermediate of Formula (III), in a suitable solvent, preferably in the absence of a phosphine or other thiophile, to induce a [2,3]-sigmatropic rearrangement therein to form an allylic sulfide of Formula (IV), with concomitant loss of chalcogen Z, as set forth in the following reaction scheme, wherein X is an activating group selected from the group consisting of CN, S-pyridyl, S-heteroaryl, SO2-aryl, and SO3Y; Y is an alkali metal ion; Z is Se or S; R1, R2, R3, R4, and R5 are each independently H or a hydrocarbon moiety; and R is an organic moiety.Type: ApplicationFiled: April 29, 2008Publication date: September 2, 2010Inventors: David Crich, Maheswaran Karatholuvhu, Venkataramanan Krishnamurthy, Thomas K. Hutton, Franck Brebion, Venkataraman Subramanian